Pfizer is considering a range of options for its consumer-products unit, including a spin off of products that could fetch top dollar, The Wall Street Journal reported yesterday.
Last year, the consumer unit reported sales of $3.88 billion, the report said.
The Journal outlined several options the company could take, including spinning off the unit to shareholders, organizing a joint venture with a consumer-products company, selling top brands such as Listerine or Dramamine or retaining the business.
The units other brands include Bengay and Visine.
While Pfizer’s prescription medicines business has long been the stronger sister within the company, sales of the consumer-products unit have grown at a faster rate than those of the company as a whole. Last year, sales in the consumer-products unit rose 10% while sales of prescription drugs fell 4%, the report said.
Network
